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Abstract 
Background: Inflammatory and degenerative activity inside the joint can be studied in vivo by analysis of synovial 
fluid biomarkers. In addition to pro‑inflammatory mediators, several anabolic and anti‑inflammatory substances are 
produced during the disease process. They counteract the catabolic effects of the pro‑inflammatory cytokines and 
thus diminish the cartilage damage. The response of synovial fluid biomarkers after intra‑articular hyaluronan injec‑
tion, alone or in combination with other substances, has been examined only in a few equine studies. The effects of 
hyaluronan on some pro‑inflammatory mediators, such as prostaglandin  E2, have been documented but especially 
the effects on synovial fluid anti‑inflammatory mediators are less studied. In animal models hyaluronan has been 
demonstrated to reduce pain via protecting nociceptive nerve endings and by blocking pain receptor channels. How‑
ever, the results obtained for pain‑relief of human osteoarthritis are contradictory. The aim of the study was to meas‑
ure the synovial fluid IL‑1ra, PDGF‑BB, TGF‑β1 and TNF‑α concentrations before and after surgically induced cartilage 
defect, and following intra‑articular hyaluronan injection in horses. Eight Standardbred horses underwent bilateral 
arthroscopic surgeries of their intercarpal joints under general anaesthesia, and cartilage defect was created on the 
dorsal edge of the third carpal bone of one randomly selected intercarpal joint of each horse. Five days post‑surgery, 
one randomly selected intercarpal joint was injected intra‑articular with 3 mL HA (20 mg/mL).
Results: Operation type had no significant effect on the synovial fluid IL‑1ra, PDGF‑BB, TGF‑β1 and TNF‑α concentra‑
tions but compared with baseline, synovial fluid IL‑1ra and TNF‑α concentrations increased. Intra‑articular hyaluronan 
had no significant effect on the biomarker concentrations but a trend of mild improvement in the clinical signs of 
intra‑articular inflammation was seen.
Conclusions: Creation of the cartilage defect and sham‑operation lead to an increase of synovial fluid IL‑1ra and 
TNF‑α concentrations but changes in concentrations of anabolic growth factors TGF‑β1 and PDGF‑BB could not be 
documented 5 days after the arthroscopy. Intra‑articular hyaluronan was well tolerated. Further research is needed to 
document possible treatment effects of intra‑articular hyaluronan on the synovial fluid biomarkers of inflammation 
and cartilage metabolism.
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Background
Research on equine joint disease has been focused on 
finding tools for early diagnosis and monitoring the treat-
ments and progression of the joint disease. Inflamma-
tory and degenerative activity in the joint can be studied 
in vivo by analysis of synovial fluid (SF) biomarkers, such 
as pro-inflammatory cytokines in experimental setting 
[1–5], or in naturally occurring joint disease [6–8]. In 
addition to pro-inflammatory mediators, several anabolic 
and anti-inflammatory mediators are produced during 
the inflammatory process. They counteract the catabolic 
effects of the pro-inflammatory cytokines and diminish 
the cartilage damage. Moreover, the anti-inflammatory 
effect can produce temporal relief of the clinical symp-
toms of the articular disease [9].
Equine arthritis is commonly treated with intra-artic-
ular (IA) corticosteroids and hyaluronan (HA) [10]. 
However, the response of SF biomarkers after IA HA 
injection, alone or in combination with other substances, 
has been examined only in a few equine studies [3, 4, 
11]. In human medicine, clinical efficacy of HA has been 
widely studied [12]. In addition, the effect of IA HA on 
some SF pro-inflammatory biomarkers, such as prosta-
glandin  E2, has been explored both in human and equine 
studies [3, 4, 13–15]. However, research on the effect 
of HA on anti-inflammatory mediators has been infre-
quently conducted. Despite the observed effects of HA 
on pro-inflammatory mediators, results in pain-relief in 
human osteoarthritis (OA) are contradictory [12]. In ani-
mal models HA has been demonstrated to reduce pain 
via protecting nociceptive nerve endings [16] and by 
blocking pain receptor channels [17].
The aim of the study was to measure SF concentrations 
of the anti-inflammatory mediator interleukin-1 receptor 
antagonist (IL-1ra), the anabolic growth factors platelet-
derived growth factor BB (PDGF-BB) and transforming 
growth factor beta-1 (TGF-β1) and the pro-inflamma-
tory cytokine tumour necrosis factor alpha (TNF-α) 
before and after surgically induced cartilage defect (CD) 
in healthy horses. Secondly, we wanted to explore if the 
concentrations of the selected biomarkers changed fol-
lowing the IA HA (non-animal stabilized hyaluronic acid, 
NASHA1) injection. The hypothesis was that both con-
centrations of anti-inflammatory cytokines and concen-
tration of TNF-α will increase in SF after the induction of 
CD; and that in the HA-injected joints the pro-inflamma-
tory TNF-α is decreased and the concentrations of anti-
inflammatory mediators are increased compared with 
the joints without the HA medication.
Methods
The study protocol was approved by the National Ani-
mal Experimental Board in Finland. Eight Standardbred 
horses (four mares, one stallion and three geldings) free 
of lameness were used. Before recruiting the horses, 
combination of interventions was randomly picked for 
each right intercarpal joint. As a result, each joint was 
selected for one of the following; cartilage defect (CD) 
with HA, CD without injection, sham-operation (SO) 
with HA or SO without injection. Interventions for each 
of the contralateral intercarpal joints were determined by 
these randomly picked combinations; i.e. if CD with HA 
was selected for the right side, left side was for SO with-
out injection.
The median age of horses was 7  years and range 
4–24  years. Examinations, grading of measured vari-
ables and surgical procedures were carried by the prin-
cipal veterinarian (TMN). Prior to inclusion, horses were 
subjected to a complete lameness examination. A stand-
ardized American Association of Equine Practitioners’ 
(AAEP) scale of 0–5 [18] was used to grade lameness. 
Effusion of the affected joint was recorded on a scale of 
0–4 (0 = no effusion, 1 = mild, 2 = moderate, 3 = severe 
effusion, 4 = severe swelling of the joint region) [19]. 
A flexion test of the affected and the contralateral limb 
was performed, and lameness was recorded on a scale 
of 0–4 (0 = no increase, 1 = slight increase, 2 = moder-
ate increase, 3 = considerable increase compared with 
the baseline lameness, 4 = non-weight-bearing lameness) 
[3]. Pain score for maximal flexion of the carpus was also 
determined and recorded on a scale of 0–3 (0 = no pain 
on flexion, 1 = mild pain, i.e. the horse shows some reac-
tion, such as moving the limb, 2 = moderate pain, i.e. the 
horse retracts the limb repeatedly during the 1 min flex-
ion period, 3 = severe pain, i.e. the flexion test cannot be 
properly performed). In addition, five radiographic views 
(dorsopalmar, dorsolateral-palmaromedial, dorsomedial-
palmarolateral, flexed lateromedial and flexed dorsoprox-
imal-dorsodistal) of the carpal joints were assessed.
Before the surgical procedure, 5 mL of the SF of both 
intercarpal joints of each horse were aspirated into a ster-
ile 5 mL syringe for the biomarker measurements. The SF 
sample was immediately divided between a plain 4  mL 
tube on ice and into an etylenediaminetetraacetic acid 
(EDTA) tube. White blood cell (WBC) count and total 
protein (TP) concentration measurements were done 
from the fresh sample in the EDTA tube. Within 1 h of 
collection, the plain sample was centrifuged at 4000 rpm 
for 10 min in 4 °C, aliquoted and stored at − 80 °C.
The horses underwent bilateral arthroscopic surger-
ies of their intercarpal joints under general anaesthesia. 
No pre-existing IA abnormalities were detected dur-
ing the arthroscopy in any of the joints. Cartilage defect 1 Durolane, Bioventus LLC, Durham, NC, USA.
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was created on the dorsal edge of the third carpal bone 
of one randomly selected intercarpal joint of each horse. 
The lesion was generated using a 5.0 mm × 13 cm arthro-
scopic burr.2 After the procedure, the debris was left in 
the joint, inducing synovitis and articular inflammation. 
Synovial membrane and joint capsule (approximately 
3  mm × 3  mm) were harvested with a scalpel from the 
dorsal region of the joints for a study to be reported 
elsewhere. The sham-operated contralateral joints (SO) 
served as controls and were similarly evaluated by arthro-
scopic examination, synovial membranes and joint cap-
sules were harvested but the cartilage was left intact. The 
arthroscopic portals were closed, forelimbs were band-
aged, and horses were allowed to recover from the anaes-
thesia and surgery. The horses were housed in stall boxes. 
The status of each horse was monitored three times daily, 
including comfort, lameness at walk, body temperature, 
heart rate and respiratory rate.
Five days post-surgery, the lameness examination was 
repeated, new SF samples from both intercarpal joints 
were harvested and one randomly selected intercarpal 
joint was injected IA with 3  mL HA (20  mg/mL). Nine 
days after the IA HA injection (i.e. 2 weeks after the sur-
gical arthroscopic procedure) the third lameness evalua-
tion was done, and the third SF sampling, and the second 
synovial soft tissue sampling of both intercarpal joints 
were performed under general anesthesia, after which 
horses were euthanized on the operating table.
Laboratory analyses
Synovial fluid samples obtained on day 0, day 5 and day 
14 were used to analyze for the concentration of IL-1ra, 
PDGF-BB, TGF-β1 and TNF-α. All markers were assayed 
using commercial ELISA development kits3, 4, 5, 6 from 
R&D Systems. Samples were analysed in triplicate. TGF-
β1 (see footnote 3) and PDGF-BB (see footnote 4) were 
determined using human antibodies. IL-1ra (see footnote 
5) and TNF-α (see footnote 6) were assayed with equine-
specific antibodies. The standards provided for each 
ELISA kit were used in preparing each standard curve 
according to the manufacturers’ instructions. Readings 
were performed at 450  nm. The inter-, and intra-assay 
coefficient of variation was < 6% for each ELISA.
Statistical methods
IL-1ra, PDGF-BB, TGF-β1, TNF-α, WBC count and TP 
concentration were analysed with analysis of covariance 
models (ANCOVA). The study design had 3 time-points 
and 2 different interventions (operation, treatment). The 
two effects were analysed separately due to small sam-
ple size. The change in biomarker and TP concentrations 
and WBC count from pre-operation to pre-treatment 
was examined in one analysis and the change from pre-
treatment to end of follow-up in another analysis. In 
both analyses, the change in concentration was used as 
the response, operation type or treatment as the fixed 
effect and the corresponding baseline measurement as a 
covariate.
As there were still some doubts about the normal-
ity of distributions after transformation, the changes in 
biomarker and TP concentrations and WBC count were 
analysed also using the Wilcoxon signed rank test. The 
Wilcoxon test was conducted also for all 16 limbs (effect 
of operation regardless of type). A P-value < 0.05 was 
accepted as statistically significant for all tests.
Results
Clinical outcomes
Five days after arthroscopy, all the horses showed signs 
of lameness and increased score in the flexion test of the 
CD-limb and effusion of the affected joint. The mean 
lameness score of the CD-limbs was 2.5, the mean flexion 
test score was 2.9 and the mean effusion score was 2.1, 
respectively. Two horses showed bilateral lameness, i.e. 
had a mildly lame SO-limb. In the SO-group, the mean 
scores of the flexion test and effusion were 1 and 1.8, 
respectively. No pain was elicited in the operated joint in 
maximal flexion in either of the groups (CD, SO).
Following trends can be seen in Fig.  1. After IA HA 
injection, the mean lameness score of the CD group with 
IA HA (CD + HA) decreased more compared to the 
group without HA-injection (CD − HA). Mild improve-
ment in the flexion test score and more pronounced 
improvement in the effusion score were observed in the 
CD affected limbs of horses after IA HA (CD + HA) com-
pared to the limbs without HA injections (CD − HA). 
Compared with CD groups, changes in the clinical scores 
and differences between the SO + HA and SO − HA 
groups were not consistent.
Biomarker outcomes
In the ANCOVA models, no statistically significant dif-
ferences in the Type III tests of fixed effects were docu-
mented: no effects were documented by the type of 
operation (CD vs. SO) or treatment (HA vs. no HA) to 
the concentrations measured in SF biomarkers. However, 
differences between the time points were revealed: the 
2 Dyonics Arthroscopic Surgery Blade, Smith & Nephew, Andover, MA, USA.
3 Human TGF-β1 DuoSet, DY240E, R&D Systems, Minneapolis, MN, USA.
4 Human PDGF-BB DuoSet, DY220, R&D Systems, Minneapolis, MN, 
USA.
5 Equine IL-1ra/IL1F3 DuoSet, DY1814, R&D Systems, Minneapolis, MN, 
USA.
6 Equine TNF-alphaDuoSet, DY1814, R&D Systems, Minneapolis, MN, 
USA.
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Fig. 1 Mean (± SEM) clinical outcome measures of treatment groups post operation (day 5) and post treatment (day 14). CD + HA cartilage defect 
joints with hyaluronan injection, CD − HA cartilage defect joints without hyaluronan injection, SO + HA sham‑operated joints with hyaluronan 
injection, SO − HA sham‑operated joints without hyaluronan injection
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change from pre-operation to pre-treatment values were 
significant for IL-1ra (P = 0.0344 in the CD group and 
P = 0.0103 in the SO group), WBC count (P = 0.011 in the 
CD group and P = 0.002 in SO group) and TP (P = 0.0002 
in the CD group and P = 0.002 in the SO group). HA had 
no significant effect on the biomarker concentrations 
within the groups.
In the Wilcoxon signed rank tests similar results were 
seen. The SF IL-1ra concentration was not significantly 
different for the operation types (CD vs. SO) but regard-
ing all limbs the SF IL-1ra concentration increased signif-
icantly after arthroscopy (P = 0.0039). Also, the increase 
in SF TNF-α concentration was significant (P = 0.0386) 
regarding all limbs. Induction of CD and SO both 
caused a significant increase within both groups in WBC 
count (P < 0.001 in both groups) and TP concentration 
(P < 0.001 in both groups).
Discussion
In the present study, the concentrations of the measured 
biomarkers in intact equine joints are mainly equivalent 
compared with the results of a previous report [20]. To 
the best of our knowledge, IL-1ra, PDGF-BB, TGF-β1 
measured in the present study have been evaluated sepa-
rately only in a few studies on SF of the equine joint [2, 
21–23]. A purely catabolic cytokine TNF-α has been 
studied in greater detail [5, 20, 21, 23–28]. Most of the 
biomarkers have been documented in vitro in equine car-
tilage as well as in the synovial membrane after a chal-
lenge, usually lipopolysaccharide (LPS) [20, 29–31].
IL-1ra has been shown to increase after an acute intra-
articular fracture in humans. However, differences in 
SF inflammatory cytokine concentrations between high 
and low-energy injuries have not been detected [32]. 
Although not directly comparable with intra-articu-
lar fractures, in the present study no differences were 
detected between CD joints and SO joints. However, 
the arthroscopy itself caused trauma to the synovial 
soft tissues and may have caused the increase of IL-1ra 
concentration.
Blocking the IL-1β receptor by IL-1ra has potentially 
a wide positive effect on inhibiting deleterious events in 
the joint. The binding of IL-1β to a receptor results in 
activation of several transcription factors and expression 
of hundreds of genes leading to the synthesis of other 
cytokines, chemokines, adhesion molecules, inflamma-
tory mediators and enzymes [33]. Consequently, IL-1β 
is has a significant effect on the metabolism of cells and 
the extracellular matrix [34]. A decrease in SF IL-1ra 
has been documented in chronic stages of human OA 
[35]. Delayed increase of SF IL-1ra (at day 35) follow-
ing the IA administration of autologous conditioned 
serum in experimentally induced equine OA has been 
demonstrated, suggesting endogenous production of 
IL-1ra [2]. In the present study, IA HA had no appar-
ent effect on SF IL-1ra concentration in the short-term. 
However, long-term effects of IA HA on SF IL-1ra war-
rants further research.
PDGF is secreted in the early inflammatory phase pri-
marily by platelets, but also by macrophages, endothelial 
cells and fibroblasts [36]. It is one of the earliest and the 
most sensible growth factors expressed after tissue injury 
[37]. PDGF induces the synthesis of other growth fac-
tors [38], proliferation and differentiation of fibroblasts, 
deposition of collagen and angiogenesis [39, 40]. There-
fore, it is an essential promoter of the healing process. In 
the present study, after sampling at the baseline on day 
0, the next sampling was performed on day 5, in a time 
point where PDGF-BB is supposed to play a major role in 
the vascular formation and proliferation of fibroblasts in 
ongoing repair [41]. PDGF-BB concentration increased 
in SF after induction of CD, although a significant dif-
ference was not detected. The synthesis of PDGF-BB 
may have, however, occurred earlier in the course of 
injury and inflammation. In contrast, PDGF-BB has not 
been detected at all in the SF of osteoarthritic human 
knee joint [42]. In another study comparing OA joints to 
healthy controls, significant differences in the SF PDGF-
BB concentrations were not detected [43]. These results 
are also suggestive for an early increase of SF PDGF-
BB concentration and its role in the initial phase of the 
pathogenesis of OA. SF PDGF concentration has been 
documented to increase after IA platelet rich plasma-
treatment [23]. In the present study, no changes in the 
PDGF-BB concentrations were documented 9 days after 
IA HA treatment.
SF TGF-β1 has been studied in  vivo in normal joints 
and joints with osteochondrosis in foals [22] and after 
LPS challenge in adult horses [21]. In the present study, 
neither the creation of CD or IA HA injection caused 
an increase in the SF TGF-β1 concentration. In contrast, 
TGF-β1 concentration decreased following the creation 
of CD, although no statistically significant difference 
between CD and SO joints was found (Fig. 2). This is dif-
ferent compared with the previous study on equine joints 
that reported increase of SF TGF-β1 concentration fol-
lowing a challenge with LPS [21]. This may be explained 
by the more intense inflammation induced by LPS, com-
pared with inflammation induced by CD.
Ríos et al. [30] has shown an increase in TGF-β1 con-
centration after LPS challenge in cartilage inflammation 
created in vitro. The effect was suggested to result from 
a possible anti-inflammatory mechanism or by direct 
damage of LPS to the cartilage. A similar effect has been 
seen after LPS challenge of synovial membrane explants 
in vitro [31]. Our result is more consistent with the study 
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of human OA where SF TGF-β concentration was meas-
ured both in healthy subjects and in patients with OA; 
in the latter, the concentration of SF TGF-β was low or 
even undetectable [44]. Cell signaling pathways may be 
intercepted by inflammatory cytokines, which may be a 
possible reason for the reduced amount of TGF-β in the 
course of OA [45].
TGF-β1 has an anabolic effect on cartilage; it has an 
ability to induce chondrogenic differentiation of mes-
enchymal stem cells [46, 47] with rapid biosynthesis of 
glycosaminoglycan and deposition of an extracellular 
matrix [47]. On the other hand, enhanced expression 
of TGF-β1 has been associated with developing osteo-
phytes [48] and hyperplasia of the synovium [49]. It has 
been suggested that only a narrow range of bioactive 
TGF-β concentrations are beneficial to cartilage health 
and any concentrations below or above this range may 
cause aberrant alterations in TGF-β pathways, resulting 
in abnormal cartilage function [50]. As TGF-β is stored 
in the platelets, SF TGF-β concentration increases after 
IA administration of platelet rich plasma, in response to 
platelet activation [23]. HA has been suggested to play 
an important role in the mechanical activation of latent 
TGF-β in the joint [51]. However, in the present study, 
no changes in the SF TGF-β1 concentrations were doc-
umented after IA HA treatment, possibly implying that 
optimal SF TGF-β1 concentrations were already present 
in the injected joints.
The results of studies on the synovial fluid TNF-α 
are somewhat contradictory. However, it seems to be 
quite a sensitive but not very specific marker of IA 
insults. The results of this study are also suggestive of 
that. TNF-α concentration increased in SF after induc-
tion of CD although significant differences were not 
detected between the groups in the small population 
of this experimental study. An increased concentration 
of SF TNF-α has been documented in horses in natu-
rally occurring OA in carpi [27], and experimentally in 
amphotericin B- [5] and LPS-induced articular inflam-
mation [21, 26]. In horses, even exercise alone leads to 
a significant increase in TNF-α levels for a short period 
[25, 28]. However, an increase in SF TNF-α concentra-
tion as a result from serial arthrocentesis could not be 
demonstrated [25]. In contrast to this, gas and liquid 
capsular distension during arthroscopy provoked an 
inflammatory response with increased concentration of 
Fig. 2 SF biomarker concentrations (median, quartiles and minimum and maximum value) of treatment groups on different sampling days. 
CD + HA cartilage defect joints with hyaluronan injection, CD − HA cartilage defect joints without hyaluronan injection, SO + HA sham‑operated 
joints with hyaluronan injection, SO − HA sham‑operated joints without hyaluronan injection
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SF TNF-α [52]. In a clinical equine study, TNF-α was 
found not to be a useful biomarker for different types 
of joint lesions [53]. Similarly, in humans, increased 
concentrations were not associated with any particular 
type of articular disease, such as rheumatoid arthritis, 
although in OA patients, detectable concentrations of 
TNF-α were related with a long duration of the dis-
ease [24]. In the present study, SF TNF-α concentra-
tions were not affected by IA HA. Probably with more 
horses, a bigger sample size and earlier and more fre-
quent sampling significant results may have been dem-
onstrated in this study.
In conclusion, after a mild increase in biomarker con-
centrations resulting from arthroscopy and induction of 
synovitis and CD, HA failed to produce any further effect 
on biomarkers. Minor improvement of clinical signs of 
IA inflammation was evident in the CD + HA group, 
when compared with scores of clinical signs of CD − HA 
group. However, in SO + HA and SO − HA groups 
changes after IA HA/no injection were not that consist-
ent. HA is reported to have an anti-inflammatory effect 
[16] but IA HA injections have also been documented to 
induce a transitional IA inflammatory reaction, either a 
flare with pronounced clinical signs of inflammation and 
pain [54] or an increase of WBC count in the SF [11]. 
To our knowledge, only a few studies have explored bio-
markers in equine SF after IA HA [3, 11]. As HA is very 
frequently used in the IA treatment in horses, its mecha-
nism of action warrants further research.
This study has its limitations. Firstly, the contralateral 
limb of the horse served as a SO control. Concentra-
tions of cartilage matrix products are elevated also in 
the contralateral knee in patients with anterior cruciate 
ligament rupture, possibly as a consequence of an altered 
loading [55]. Cytokines and degraded matrix products 
released from an operated joint may be transported to 
the contralateral joint by the circulation and initiate an 
inflammatory process. Therefore, the concentration of 
markers in the control joints may have resulted partly 
by the transport from the CD operated joint. Measure-
ment of serum concentrations of studied markers, as 
well as additional pro-inflammatory markers and mark-
ers of cartilage matrix metabolism, would have provided 
additional information to test this hypothesis. However, 
this was outside the scope of this study. Moreover, the 
arthroscopy itself, as well as harvesting the synovial tis-
sue samples, causes trauma to the synovial soft tissues. 
These may have further affected the concentrations of the 
measured markers in the SO joints. However, the effect 
was thought to be transient. To minimize the effect of 
arthroscopy and sampling of synovial soft tissue, sam-
pling of SF and IA HA injection were performed only 
after 5 days.
The number of horses in the experimental studies on 
equine joints has generally ranged from 6 to 13 [1, 3, 5, 
21, 26, 52]. Eight horses (16 joints) in the present study 
may have been too low to detect differences in concen-
trations of SF biomarkers. Although horses with uniform 
breed and sport discipline were selected, and all horses 
were free of lameness and joint disease of the intercar-
pal joint as verified by arthroscopy, differences in exercise 
or training status and age may have caused some varia-
tion in the SF biomarker concentrations. Exercise may 
lead to increased biomarker concentrations in horses [7, 
28], which can be further enhanced in joints with com-
promised health [7, 25]. Moreover, also age has been 
reported to influence SF biomarker concentrations or 
gene expression so that they generally decrease with age 
[8, 29, 56].
The time from injury to collection of SF samples is 
an important issue as changes in biomarker concentra-
tions can occur quickly, even within hours. On the other 
hand, IA injection itself, especially repeatedly, causes 
inflammatory reaction in the joint [57] and can cause 
increases in biomarker concentrations [56]. To minimize 
this effect, it has been recommended there should be a 
period of even 14 days after the previous arthrocentesis 
before subsequent SF collection [28]. However, despite of 
these potentially interfering factors, repeated sampling 
and early time points have been generally used in equine 
SF biomarker studies. In studies using LPS induction 
for IA inflammation, first sampling point 8 h [19] or 1 h 
[21, 26] post injection were chosen which is reasonable 
considering very acute and strong inflammation caused 
by LPS. On the other hand, in some experimental stud-
ies, using surgical model [3, 4] comparable with model of 
the present study or amphotericin B [5] for induction of 
IA inflammation in horses, weekly samplings were cho-
sen for exploring SF IL-1ra and TNF-α concentrations 
(among other biomarkers), respectively. Finding an opti-
mal time point for SF aspiration is challenging, especially 
when several biomarkers are studied. In addition, avoid-
ing the effect of repeated aspiration and sham-opera-
tion on biomarker concentrations complicates the issue. 
Although the effect of IA injection on biomarkers meas-
ured in this study is not known, except for TNF-α, 5 days 
after arthroscopy and 9 days after IA HA injection were 
chosen to balance between the intervention time points.
Conclusions
This study demonstrates that arthroscopy and both the 
creation of CD and SO, lead to an increase in SF IL-1ra 
and TNF-α concentrations but changes in concentrations 
of anabolic growth factors TGF-β1 and PDGF-BB in SF 
were not documented 5 days after the arthroscopy. Intra-
articular HA was well tolerated. However, changes in 
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concentrations of IL-1ra, PDGF-BB, TGF-β, and TNF-α 
were not seen after HA injection. The treatment effect of 
IA HA on SF pro-inflammatory, anti-inflammatory and 
anabolic biomarkers warrants further research.
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